13 results
·
19ms
·
Sources: EU EUDAMED, US FDA
Filters
Regulation: Us FDA
×
PHOSPHORUS-SL ASSAY, CATALOGUE NUMBER 117-10, 117-30
FDA 510(k)
FDA Class 1
·Clinical Chemistry
ACE OPEN-BACK HALO RING
FDA 510(k)
FDA Class 2
·Orthopedic
LASERTRIPTER MINISCOPE
FDA 510(k)
FDA Class 2
·Gastroenterology, Urology
PSO KNEE BONE SUBSTITUTION
FDA Adverse Event
Injury
·BIOMET SPAIN, S.L.·Product code KRO·April 22, 2022
PSO KNEE BONE SUBSTITUTION
FDA Adverse Event
Injury
·BIOMET SPAIN, S.L.·Product code KRO·July 18, 2019
MORPHEUS PICC
FDA Adverse Event
Malfunction
·ANGIODYNAMICS·Product code LJS·June 11, 2014
ONETOUCHPING GLUCOSEMGMTSYSTEM
FDA Adverse Event
Malfunction
·ANIMAS CORPORATION·Product code LZG·February 22, 2013
PRECISION TEST STRIPS
FDA Adverse Event
Malfunction
·ABBOTT DIABETES CARE, INC. USA·Product code NBW·January 31, 2011
UNKNOWN HEAD
FDA Adverse Event
Injury
·ZIMMER BIOMET, INC.·Product code KWA·February 16, 2018
NFORCE NITINOL HELICAL STONE EXTRACTOR
FDA Adverse Event
Malfunction
·COOK INC·Product code FFL·June 13, 2019
BioButton REF BIOST06040 with Software version 3.0.20 The BioButton System is a remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings while the patient is at rest.
FDA Enforcement
Class II
·Ongoing·Biointellisense Inc.·August 21, 2024
Exactech Equinoxe REVERSE SHOULDER,36mm Humeral Liner: a) +0mm, Item Number 320-36-00, b) +2.5mm, Item Number 320-36-03; Shoulder Arthroplasty
FDA Enforcement
Class II
·Ongoing·Exactech, Inc.·April 10, 2024
Anthem Model Numbers: PM3210, PM3212; Allure/Relieve Model Numbers: PM3222, PM3242, PM3262, PM3542, PM3224, PM3244 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration
FDA Enforcement
Class II
·Terminated·St Jude Medical Inc.·October 25, 2017